Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06316102
Other study ID # 22-3282
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date July 14, 2023
Est. completion date January 1, 2025

Study information

Verified date February 2024
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study includes an adapted multilevel intervention, Abriendo Puertas (Opening Doors), including individual counseling, peer navigation, and community mobilization for transfeminine people living with HIV in the Dominican Republic using an iterative consultation process. Prior to this randomized controlled trial, feasibility and initial effects on HIV care and treatment behaviors were assessed with 30 trans women living with HIV (no control group) and documented positive trends in antiretroviral therapy use (70% to 85%, p=0.03), missed care appointments (35% to 20%, p=0.39) and antiretroviral therapy adherence (86% to 96%, p=0.50). Participants emphasized that trusting intervention staff and being treated with respect in individual sessions allowed them to improve self-esteem. Limited trust and cohesion among trans women, however, inhibited more extensive engagement with peer navigation and community activities. In response, the study team identified two key modifications to strengthen and further tailor the intervention for transfeminine people living with HIV: 1) integrate more gender affirming content, including with providers and 2) focus on building trust among transfeminine people through sequential implementation of individual and then community components. The purpose of the proposed study is to conduct a pilot randomized trial of the Gender-affirming Abriendo Puertas intervention. In Aim 1, the preliminary efficacy of the Gender-affirming Abriendo Puertas intervention on viral suppression among transfeminine people randomized to the intervention compared to those randomized to control will be assessed. The research study will randomly assign transfeminine people living with HIV to the Gender-affirming Abriendo Puertas intervention (n=60) (individual counseling, peer navigation, provider training, and community support building) or control group (n=60). There will be baseline, 6, and 12-month surveys and viral load assessments to assess differences across study arms. In Aim 2, the study team will examine pathways of influence (e.g. decreased stigma, increased cohesion) and experiences with the intervention to identify specific areas for improvement and scale up. Longitudinal qualitative interviews will be conducted at baseline, 6, and 12 months with 20 intervention participants. Together with surveys, the study team will assess how Gender-affirming Abriendo Puertas participation affects pathways between stigma, cohesion, and HIV outcomes. The study team will also elicit experiences and recommendations from providers and intervention staff in focus groups at 6 (n=2) and 12 months (n=2).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 121
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - being at least 18 years of age; - assigned male at birth but self-identify as transfeminine (using locally appropriate terminology); - confirmed HIV positive diagnosis using a single rapid test Exclusion Criteria: - There is a small group of individuals (approximately 20) who participated in a previous adaptation study to develop the intervention that will be tested in the proposed study. These individuals will not be eligible since they have already been exposed to an earlier version of the intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Gender Affirming Abriendo Puertas (Opening Doors) (GAP)
Multilevel intervention with 4 components

Locations

Country Name City State
Dominican Republic Instituto Dermatológico y Cirugía de Piel (IDCP) Santo Domingo

Sponsors (3)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill George Washington University, Instituto Dermatológico y Cirugía de Piel (IDCP)

Country where clinical trial is conducted

Dominican Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary Viral Suppression (HIV), 6 months For viral load assessments of HIV, a 10 mL tube of ethylenediaminetetraacetic acid anti-coagulated blood will be drawn.
<400 copies/mL= viral suppression >=400 copies/mL=no viral suppression
6 months
Primary Viral Suppression (HIV), 1 year For viral load assessments of HIV, a 10 mL tube of ethylenediaminetetraacetic acid anti-coagulated blood will be drawn.
<400 copies/mL= viral suppression >=400 copies/mL=no viral suppression
1 year
Primary Retention in HIV care, 6 months Participants who have received HIV care will answer the question:
In the past 6 months, how many HIV appointments have you missed? 0 = Retention in HIV care >0 = No retention in HIV care
6 months
Primary Retention in HIV care, 1 year Participants who have received HIV care will answer the question:
In the past 6 months, how many HIV appointments have you missed? 0 = Retention in HIV care >0 = No retention in HIV care
1 year
Primary Antiretroviral therapy adherence, 6 months Participants on antiretroviral therapy will be asked:
During the last 4 days, how many days did you not take your entire antiretroviral therapy dose? 0 = No antiretroviral therapy interruption >0 = Antiretroviral therapy interruption
6 months
Primary Antiretroviral therapy adherence, 1 year Participants on antiretroviral therapy will be asked:
During the last 4 days, how many days did you not take your entire antiretroviral therapy dose? 0 = No antiretroviral therapy interruption >0 = Antiretroviral therapy interruption
1 year
Primary Antiretroviral therapy interruption, 6 months Participants on antiretroviral therapy will be asked:
In the past 6 months, have you stopped or suspended your antiretrovirals?
No = No antiretroviral therapy interruption Yes = Antiretroviral therapy interruption
6 months
Primary Antiretroviral therapy interruption, 1 year Participants on antiretroviral therapy will be asked:
In the past 6 months, have you stopped or suspended your antiretrovirals?
No = No antiretroviral therapy interruption Yes = Antiretroviral therapy interruption
1 year
Secondary Depression, 6 months Patient Health Questionnaire-9: 0-9=No depressive symptoms; 10-27=depressive symptoms.
Response options:
No day, Several days, More than half the days, Almost every day
Items about previous 2 weeks:
You have little interest or pleasure in doing things. You have felt down, depressed, or hopeless. You have had difficulty staying or falling asleep or you have slept too much You have felt tired or with little energy You have had little appetite or have eaten excessively You have felt badly about yourself - or you think you are a failure or that you have done wrong to yourself or your family You have had difficulty concentrating on certain activities, like watching tv or movies You have moved or talked so slowly that other people noticed it You have been so restless or agitated that you have been moving more than normal and others have noticed it You have thought that you would be better off dead or you have thought about harming yourself in some way
6 months
Secondary Depression, 1 year Patient Health Questionnaire-9: 0-9=No depressive symptoms; 10-27=depressive symptoms.
Response options:
No day, Several days, More than half the days, Almost every day
Items about previous 2 weeks:
You have little interest or pleasure in doing things. You have felt down, depressed, or hopeless. You have had difficulty staying or falling asleep or you have slept too much You have felt tired or with little energy You have had little appetite or have eaten excessively You have felt badly about yourself - or you think you are a failure or that you have done wrong to yourself or your family You have had difficulty concentrating on certain activities, like watching tv or movies You have moved or talked so slowly that other people noticed it You have been so restless or agitated that you have been moving more than normal and others have noticed it You have thought that you would be better off dead or you have thought about harming yourself in some way
1 year
Secondary Anxiety, 6 months positive screening for anxiety symptoms in the previous 2 weeks. Measured using the Hospital Anxiety and Depression Scale - Anxiety which consists of 7 items.
Score 0-7 = No anxiety symptoms Score 8-21 = anxiety symptoms
Items:
I feel tense or nervous
All the times, many times, sometimes, never I have a strange feeling, as if there were butterflies in my stomach
Never, on occasion, frequently, very often I have a sense of fear, as if something horrible were going to happen to me
Definitely and it is very strong, yes but no too strongly, a little but it doesn't worry me, never I feel restless, as if I couldn't stop moving
A lot, a good deal, not much, never My mind is full of worries
most of the time, frequently, sometimes but not often, only on occasion Sudden feelings of panic come over me
very frequently, often, not often, rarely I can sit comfortably and feel relaxed
always, generally, not often, never
6 months
Secondary Anxiety, 1 year positive screening for anxiety symptoms in the previous 2 weeks. Measured using the Hospital Anxiety and Depression Scale - Anxiety which consists of 7 items.
Score 0-7 = No anxiety symptoms Score 8-21 = anxiety symptoms
Items:
I feel tense or nervous
All the times, many times, sometimes, never I have a strange feeling, as if there were butterflies in my stomach
Never, on occasion, frequently, very often I have a sense of fear, as if something horrible were going to happen to me
Definitely and it is very strong, yes but no too strongly, a little but it doesn't worry me, never I feel restless, as if I couldn't stop moving
A lot, a good deal, not much, never My mind is full of worries
most of the time, frequently, sometimes but not often, only on occasion Sudden feelings of panic come over me
very frequently, often, not often, rarely I can sit comfortably and feel relaxed
always, generally, not often, never
1 year
Secondary Substance use, 6 months Yes = used any type of drug in the previous 6 months No = did not use any type of drug in the previous 6 months 6 months
Secondary Substance use, 1 year Yes = used any type of drug in the previous 6 months No = did not use any type of drug in the previous 6 months 1 year
Secondary Binge drinking, 6 months No = consumes 6+ drinks on one occasion less than once a month Yes = consume 6+ drinks on one occasion at least monthly 6 months
Secondary Binge drinking, 1 year No = consumes 6+ drinks on one occasion less than once a month Yes = consume 6+ drinks on one occasion at least monthly 1 year
Secondary Self-esteem, 6 months Rosenberg self-esteem scale; analyzed as a continuous variable. A higher score indicates higher self-esteem
Response options:
Totally agree = 4 Agree = 3 Disagree = 2 Totally disagree = 1
Items:
In general, I am satisfied with myself Sometimes, I think I am not good at anything I feel like I have some good qualities I am capable of doing things as well as the majority of people I feel like I don't have many things to feel proud about Sometimes I feel really useless I feel like I am worth less than most people I wish to respect myself more Definitively, I think I am a failure I have a positive attitude toward myself
*Items 2, 5, 6, 8, 9 are reverse scored.
6 months
Secondary Self-esteem, 1 year Rosenberg self-esteem scale; analyzed as a continuous variable. A higher score indicates higher self-esteem
Response options:
Totally agree = 4 Agree = 3 Disagree = 2 Totally disagree = 1
Items:
In general, I am satisfied with myself Sometimes, I think I am not good at anything I feel like I have some good qualities I am capable of doing things as well as the majority of people I feel like I don't have many things to feel proud about Sometimes I feel really useless I feel like I am worth less than most people I wish to respect myself more Definitively, I think I am a failure I have a positive attitude toward myself
*Items 2, 5, 6, 8, 9 are reverse scored.
1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2